

Supplementary Table S1. Clinical and demographics information of patient samples.

Sample ID	Age (yrs)	Gender	Tobacco usage*	Histological dx†	TNM stage‡ NA=not applicable for dysplasia or not available for SCC	Anatomic site in oral cavity	Time to progression for low-grade lesions (months)
Oral47	67	M	NS	HN	NA	Tongue	10
Oral48	77	F	FS	Mod Dys	NA	Tongue	39
Oral50	74	F	NS	Mild Dys	NA	Tongue	31
Oral52	55	F	FS	VH	NA	Gingiva	26
Oral53	40	F	NS	Mod Dys	NA	Tongue	58
Oral54	40	F	NS	Mod Dys	NA	Tongue	14
Oral55	39	F	NS	Mod Dys	NA	Tongue	60
Oral1	76	M	FS	Sev Dys	NA	Soft palate	-
Oral2	82	F	NS	CIS	0	Tongue	-
Oral3	57	M	S	CIS	0	Floor of mouth	-
Oral4	57	F	FS	CIS	0	Tongue	-
Oral5	71	F	NA	Sev Dys	NA	Tongue	-
Oral6	73	F	NA	Sev Dys	NA	Mandibular ridge	-
Oral7**	67	M	S	Sev Dys	NA	Lip	-
Oral8	65	F	FS	Sev Dys	NA	Tongue	-
Oral9	46	F	S	CIS	0	Tongue	-
Oral10	49	M	NS	Sev Dys	NA	Tongue	-
Oral11	72	M	S	CIS	0	Soft palate	-
Oral12	77	F	NS	CIS	0	Tongue	-
Oral13	64	F	FS	Sev Dys	NA	Palate	-
Oral14	72	F	S	CIS	0	Tongue	-
Oral15	71	F	NA	Sev Dys	NA	Tongue	-
Oral16	50	F	NA	Sev Dys	NA	Floor of mouth	-
Oral17	78	M	NA	Sev Dys	NA	Palate	-
Oral18	58	M	S	Sev Dys	NA	Tongue	-
Oral19	63	F	NS	CIS	0	Gingiva	-
Oral20	44	F	NS	CIS	0	Tongue	-
Oral21	44	F	NS	CIS	0	Tongue	-
Oral22	67	M	FS	CIS	0	Palate	-
Oral23	62	M	S	CIS	0	Tongue	-
Oral24	68	F	S	Sev Dys	NA	Floor of mouth	-
Oral25	67	M	FS	Sev Dys	NA	Tongue	-
Oral26	48	M	S	Sev Dys	NA	Tongue	-
Oral29	74	M	FS	CIS	0	Floor of mouth	-

Oral30	58	F	FS	CIS	0	Tongue	-
Oral31	86	M	FS	CIS	0	Tongue	-
Oral32	66	M	NS	CIS	0	Tongue	-
Oral33	52	M	S	CIS	0	Tongue	-
Oral34	58	M	NA	CIS	0	Floor of mouth	-
Oral35	57	F	NA	CIS	0	Floor of mouth	-
Oral37	56	M	FS	CIS	0	Tongue	-
Oral38	51	F	NS	Sev Dys	NA	Tongue	-
Oral40	63	M	NA	Sev Dys	NA	Floor of mouth	-
Oral41	60	M	S	Sev Dys	NA	Tongue	-
Oral42	60	F	S	CIS	0	Tongue	-
Oral43	62	M	S	Sev Dys	NA	Floor of mouth	-
Oral44	46	F	NS	Sev Dys	NA	Tongue	-
Oral45	73	F	FS	Sev Dys	NA	Tongue	-
Oral46	43	M	S	Sev Dys	NA	Sublingual mucosa	-
Oral68	38	F	NA	Sev Dys	NA	Tongue	-
Oral56	75	F	NA	Mod Dys	NA	Vestibule	Never progress since 1995
Oral58	60	F	NS	VH	NA	Gingiva	Never progress since 2000
Oral59	63	F	NS	Mild Dys	NA	Tongue	Never progress since 1999
Oral60	42	M	NS	Mod Dys	NA	Buccal	Never progress since 1995
Oral61	44	M	FS	Mild Dys	NA	Palate	Never progress since 2000
Oral62	55	M	FS	Mod Dys	NA	Tongue	Never progress since 2000
Oral63	71	F	FS	Mod Dys	NA	Tongue	Never progress since 2000
Oral64	40	F	S	Mod Dys	NA	Floor of mouth	Never progress since 2000
Oral65	65	M	FS	Mod Dys	NA	Soft palate	Never progress since 2000
Oral66	66	M	S	Mod Dys	NA	Gingiva	Never progress since 2000
Oral67	61	F	FS	Mod Dys	NA	Tongue	Never progress since 2001
Oral69	71	F	FS	Mild Dys	NA	Floor of mouth	Never progress since 2003
Oral70	52	F	NS	Mild Dys	NA	Gingiva	Never progress since 2002
Oral71	50	F	FS	Mod Dys	NA	Buccal	Never progress since 2003
Oral72	35	M	NS	SCC	1	Tongue	-

Oral73	64	M	S	SCC	2	Tongue	-
Oral74	74	F	NS	SCC	4A	Vestibule	-
Oral75	47	M	NA	SCC	2	Tongue & Floor of mouth	-
Oral76	78	M	NS	SCC	1	Lower lip	-
Oral77	73	F	FS	SCC	4A	Gingiva	-
Oral78	47	M	S	SCC	NA	Floor of mouth	-
Oral79	74	M	NS	SCC	4A	Mandible	-
Oral80**	67	M	S	SCC	3	Tongue	-
Oral81	46	M	S	SCC	2	Soft palate	-
Oral82	42	M	NS	SCC	4A	Tongue	-
Oral83	55	M	FS	SCC	4A	Hard palate	-
Oral84	43	M	NA	SCC	1	Tongue	-
Oral85	65	M	S	SCC	3	Tongue	-
Oral86	59	M	NS	SCC	3	Tonsillar pillar	-
Oral87	79	F	NA	SCC	3	FOM, mandibular & submandibular glands	-
Oral88	27	M	NS	SCC	1	Tongue	-
Oral89	44	M	NA	SCC	NA	Tongue	-
Oral90	81	M	S	SCC	2	Tongue	-
Oral91	68	F	NS	SCC	1	Tongue	-
Oral92	61	M	S	SCC	2	Tongue	-
Oral93	40	M	FS	SCC	4	Tonsil	-
Oral94	33	M	NA	SCC	1	Tongue	-

*Tobacco usage: S=current smoker; FS=former smoker; NS=never smoked; NA=not available.

†Histological dx: HN, hyperplasia; VH, verrucous hyperplasia; Mild Dys, mild dysplasia; Mod dys, moderate dysplasia; CIS, carcinoma *in situ*; SCC, squamous cell carcinoma.

‡TNM, tumor-node-metastasis

** Samples Oral7 and Oral80 are from the same patient.

Supplementary Table S2. Public head and neck cancer and oral cancer datasets used in expression analysis of amplified genes.

Oncomine study name	Array Type	Sample N (SCC)	Sample N (normal)	Journal	Reference
Ginos_Head-Neck	Affymetrix Human Genome U133A Array	41 HNSCC	13 normal oral mucosa	Cancer Res.	Ginos, MA <i>et al.</i> 2004
Pyeon_Multi-cancer	Affymetrix Human Genome U133 Plus 2.0 Array	42 HNSCC	14 normal	Cancer Res.	Pyeon, D <i>et al.</i> 2007
Cromer_head-neck	Affymetrix, Human Genome U95A/Av2 Array	34 HNSCC	4 normal uvula	Oncogene	Cromer, A <i>et al.</i> 2004
Chung_Head-Neck	Agilent Human 1 cDNA microarray	55 HNSCC	3 normal tonsil	Cancer Cell	Chung, CH <i>et al.</i> 2004
Toruner_Head-Neck	Affymetrix Human Genome U133A Array	16 OSCC	4 normal oral squamous cell epithelium	Cancer Genet. Cytogenet.	Toruner, GA <i>et al.</i> 2004
GEO accession for oral cancer-specific datasets:	Array Type	Sample N (SCC)	Sample N (normal)	Journal	Reference
GSE10121	Operon Human Genome Oligo Set v4.0	35 OSCCs	6 oral mucosa	-	-
GSE9844	Affymetrix Human Genome U133 Plus 2.0 Array	26 tongue SCC	12 normal	BMC Genomics	Ye, H <i>et al.</i> 2008

Supplementary Table S3. Regions of gene amplification and homozygous deletion identified in OSCCs.

Sample	Chromosome	BP start	BP end	Size (Mb)	Amplification/deletion
Oral80	1	1664960	4121175	2.46	Amplification
Oral80	1	8137673	11057241	2.92	Amplification
Oral80	1	41363680	44254683	2.89	Amplification
Oral86	1	119383214	120039269	0.66	Amplification
Oral80	1	180681326	181362117	0.68	Amplification
Oral86	2	119406048	124375506	4.97	Amplification
Oral80	2	120606592	122213759	1.61	Amplification
Oral79	2	174017812	174508955	0.49	Amplification
Oral79	3	66951289	68455957	1.50	Amplification
Oral86	3	149968605	150998752	1.03	Amplification
Oral80	3	172915439	173631614	0.72	Amplification
Oral86	3	182476185	185427054	2.95	Amplification
Oral80	3	190327158	191835524	1.51	Amplification
Oral74	5	197527	1562881	1.37	Amplification
Oral79	6	41836818	42444246	0.61	Amplification
Oral79	7	52712918	56463747	3.75	Amplification
Oral75	7	53679954	57838439	4.16	Amplification
Oral85	7	54211661	55296490	1.08	Amplification
Oral75	7	62196113	62981658	0.79	Amplification
Oral83	7	99680294	101581563	1.90	Amplification
Oral80	7	154155214	155739542	1.58	Amplification
Oral77	8	102005665	102360864	0.36	Amplification
Oral77	8	101234578	101749095	0.51	Amplification
Oral77	8	103996539	104419139	0.42	Amplification
Oral90	8	133156891	136544201	3.39	Amplification
Oral86	8	142097444	142685278	0.59	Amplification
Oral88	9	13674530	14761740	1.09	Deletion
Oral88	9	21201965	22290129	1.09	Deletion
Oral75	10	168166	908109	0.74	Amplification
Oral80	10	2888173	6478711	3.59	Amplification
Oral72	11	34449322	36985885	2.54	Amplification
Oral83	11	44527648	47208523	2.68	Amplification
Oral81	11	55802749	57008121	1.21	Amplification
Oral87	11	65790600	71745403	5.95	Amplification
Oral88	11	68042959	72374541	4.33	Amplification
Oral80	11	68149145	71048199	2.90	Amplification
Oral83	11	68311392	72374541	4.06	Amplification
Oral74	11	68463939	69118628	0.65	Amplification

Oral81	11	68463939	70379067	1.92	Amplification
Oral74	11	101123144	103852820	2.73	Amplification
Oral89	11	101247709	103852820	2.61	Amplification
Oral88	12	68957524	70047717	1.09	Amplification
Oral75	17	33865615	35694425	1.83	Amplification
Oral75	18	14045377	14975939	0.93	Amplification
Oral84	18	17484636	19164296	1.68	Amplification
Oral80	19	42534250	44786412	2.25	Amplification
Oral79	20	30235601	32173390	1.94	Amplification
Oral75	22	35308342	38605066	3.30	Amplification

Supplementary Table S4. RefSeq genes mapped within regions of homozygous deletions.

RefSeq genes	Chromosome location
BNC2	9p22.3
ASTN2	9q33.1
TLR4	9q33.1
C9orf82	9p21.1.-p21.2
PLAA	9p21.1.-p21.2
IFT74	9p21.1.-p21.2
LRRC19	9p21.1.-p21.2
TEK	9p21.1.-p21.2
C9orf11	9p21.1.-p21.2
MOBKL2B	9p21.1.-p21.2
IFNK	9p21.1.-p21.2
C9orf72	9p21.1.-p21.2
LINGO2	9p21.1.-p21.2
NFIB	9p22.3-p23
ZDHHC21	9p22.3-p23
CER1	9p22.3-p23
FREM1	9p22.3-p23
IFNA14	9p21.3
IFNA16	9p21.3
IFNA17	9p21.3
IFNA5	9p21.3
IFNA6	9p21.3
KLHL9	9p21.3
IFNA13	9p21.3
IFNA2	9p21.3
IFNA8	9p21.3
IFNA1	9p21.3
IFNE1	9p21.3
MTAP	9p21.3
CDKN2A	9p21.3
CDKN2B	9p21.3
MGA	15q15.1
MAPKBP1	15q15.1
JMJD7-PLAG2G4B	15q15.1
JMJD7	15q15.1
SPTBN5	15q15.1
EHD4	15q15.1
PLA2G4E	15q15.1
PLA2G4D	15q15.1
PLA2G4F	15q15.1

VPS39	15q15.1
TMEM87A	15q15.1
GANC	15q15.1
CAPN3	15q15.1
WVOX	16q23.1

Supplementary Table S5. Functions of cancer-related genes within recurrent regions of amplification as determined by IPA Functional Analysis.

Category	Function	Function Annotation	P-value	Molecules	# Molecules
Cancer	von Hippel-Lindau syndrome	von Hippel-Lindau syndrome	1.31E-05	CCND1, EGFR, KDR	3
Cancer	giant cell glioblastoma	giant cell glioblastoma	4.75E-05	EGFR, KDR	2
Cancer	chemotaxis	chemotaxis of tumor cell lines	8.64E-05	CCL19, CCL21, CCL27, CREB3, EGFR	5
Cancer	homing	homing of tumor cell lines	1.06E-04	CCL19, CCL21, CCL27, CREB3, EGFR	5
Cancer	gliosarcoma	gliosarcoma	2.36E-04	EGFR, KDR	2
Cancer	cell cycle progression	cell cycle progression of brain cancer cell lines	1.02E-03	CCND1, EGFR	2
Cancer	G2 phase	arrest in G2 phase of breast cancer cell lines	1.20E-03	CCND1, EGFR	2
Cancer	pituitary gland tumor	pituitary gland tumor	1.40E-03	CCND1, EGFR	2
Cancer	renal tumor	renal tumor	1.57E-03	CA9, CCND1, EGFR, KDR	4
Cancer	pituitary cancer	pituitary cancer	1.61E-03	CCND1, EGFR	2
Cancer	hyperplasia	hyperplasia of mammary gland	1.84E-03	CCND1, FGF3	2
Cancer	invasion	invasion of breast cell lines	1.84E-03	EGFR, FGF4	2
Cancer	cell death	cell death of tumor cells	1.87E-03	CCL27, EGFR, KDR, RECK, SNAI2	5
Cancer	autosomal recessive polycystic kidney disease	autosomal recessive polycystic kidney disease	2.08E-03	CCND1, EGFR	2
Cancer	cell movement	cell movement of tumor cell lines	2.18E-03	CCL19, CCL21, CCL27, CREB3, EGFR	5
Cancer	cell cycle progression	arrest in cell cycle progression of tumor cell lines	2.45E-03	CCND1, EGFR, GAL	3
Cancer	hyperplasia	hyperplasia of exocrine gland	2.60E-03	CCND1, FGF3	2
Cancer	small cell lung carcinoma	small cell lung carcinoma	2.60E-03	EGFR, KDR	2
Cancer	G2 phase	G2 phase of breast cancer cell lines	2.88E-03	CCND1, EGFR	2

Cancer	proliferation	proliferation of squamous cell carcinoma cell lines	3.18E-03	CCND1, EGFR	2
Cancer	tumorigenesis	tumorigenesis of mammary gland	3.48E-03	CCND1, FGF3	2
Cancer	apoptosis	apoptosis of squamous cell carcinoma cell lines	3.81E-03	CCND1, EGFR	2
Cancer	peritoneal tumor	peritoneal tumor	3.81E-03	EGFR, KDR	2
Cancer	development	development of malignant tumor	3.91E-03	CCND1, EGFR, SNAI2	3
Cancer	cell cycle progression	cell cycle progression of prostatic adenocarcinoma cells	4.03E-03	CCND1	1
Cancer	hyperplasia	hyperplasia of ampullary gland	4.03E-03	FGF3	1
Cancer	hyperplasia	hyperplasia of prostatic lobe	4.03E-03	FGF3	1
Cancer	proliferation	proliferation of squamous carcinoma cells	4.03E-03	EGFR	1
Cancer	development	development of mesenchymal tumor	4.03E-03	SNAI2	1
Cancer	development	development of oligoastrocytoma	4.03E-03	EGFR	1
Cancer	development	development of oligodendroglioma	4.03E-03	EGFR	1
Cancer	S phase	entry into S phase of melanoma cell lines	4.03E-03	CCND1	1
Cancer	adhesion	adhesion of ovarian cancer cell lines	4.03E-03	EGFR	1
Cancer	adhesion	adhesion of squamous carcinoma cells	4.03E-03	EGFR	1
Cancer	growth	delay in growth of breast cancer cell lines	4.03E-03	CA9	1
Cancer	interstitial fluid pressure	interstitial fluid pressure of tumor tissue	4.03E-03	KDR	1
Cancer	morphology	morphology of squamous carcinoma cells	4.03E-03	EGFR	1
Cancer	sub-G1 phase	sub-G1 phase of colorectal cancer cell lines	4.03E-03	EGFR	1
Cancer	carcinoid tumor	carcinoid tumor	4.14E-03	EGFR, KDR	2
Cancer	growth	growth of breast cancer cell lines	4.19E-03	CA9, CCND1, EGFR, FGF4	4
Cancer	cell death	cell death of squamous cell carcinoma cell lines	4.49E-03	CCND1, EGFR	2
Cancer	growth	growth of colorectal cancer cell lines	4.49E-03	CCND1, EGFR, KDR	3
Cancer	developmental process	developmental process of breast cancer cell lines	4.57E-03	CA9, CCND1, EGFR, FGF4	4
Cancer	development	development of primary tumor	4.96E-03	CCND1, EGFR, SNAI2	3
Cancer	developmental process	developmental process of colorectal cancer cell lines	5.12E-03	CCND1, EGFR, KDR	3
Cancer	hyperplasia	hyperplasia of secretory structure	5.23E-03	CCND1, FGF3	2

Cancer	proliferation	proliferation of neuroblastoma cell lines	5.23E-03	CCND1, GAL	2
Cancer	small cell lung cancer	small cell lung cancer	5.61E-03	EGFR, GAL	2
Cancer	differentiation	differentiation of neuroblastoma cell lines	6.01E-03	CCND1, EGFR	2
Cancer	polycystic kidney disease	polycystic kidney disease	6.01E-03	CCND1, EGFR	2
Cancer	invasion	invasion of eukaryotic cells	6.31E-03	CCL19, CCL21, CCND1, EGFR, FGF4, RECK	6
Cancer	cell division process	cell division process of brain cancer cell lines	6.43E-03	CCND1, EGFR	2
Cancer	invasion	invasion of carcinoma cell lines	6.85E-03	CCL21, RECK	2
Cancer	thyroid carcinoma	thyroid carcinoma	6.85E-03	EGFR, KDR	2
Cancer	apoptosis	apoptosis of tumor cells	7.16E-03	CCL27, EGFR, KDR, SNAI2	4
Cancer	invasion	invasion of cells	7.88E-03	CCL19, CCL21, CCND1, EGFR, FGF4, RECK	6
Cancer	esophageal cancer	esophageal cancer	7.96E-03	CCND1, EGFR, KDR	3
Cancer	chemotaxis	chemotaxis of squamous cell carcinoma cell lines	8.04E-03	CCL19	1
Cancer	homing	homing of squamous cell carcinoma cell lines	8.04E-03	CCL19	1
Cancer	cell cycle progression	arrest in cell cycle progression of rhabdoid cell lines	8.04E-03	CCND1	1
Cancer	cell cycle progression	cell cycle progression of carcinoma cells	8.04E-03	CCND1	1
Cancer	cell cycle progression	cell cycle progression of prostate cancer cells	8.04E-03	CCND1	1
Cancer	tumorigenesis	delay in tumorigenesis of kidney cancer cell lines	8.04E-03	EGFR	1
Cancer	tumorigenesis	tumorigenesis of embryonic cell lines	8.04E-03	EGFR	1
Cancer	tumorigenesis	tumorigenesis of gonadal cell lines	8.04E-03	FGF3	1
Cancer	development	development of astrocytoma	8.04E-03	EGFR	1
Cancer	development	development of rhabdoid tumor	8.04E-03	CCND1	1
Cancer	S phase	S phase of melanoma cell lines	8.04E-03	CCND1	1

Cancer	morphology	morphology of carcinoma cells	8.04E-03	EGFR	1
Cancer	cell division process	cell division process of prostate cancer cells	8.04E-03	CCND1	1
Cancer	esophageal cancer	esophageal cancer of mammalia	8.04E-03	CCND1	1
Cancer	esophageal cancer	esophageal cancer of mice	8.04E-03	CCND1	1
Cancer	esophageal cancer	esophageal cancer of rodents	8.04E-03	CCND1	1
Cancer	G0/G1 phase transition	arrest in G0/G1 phase transition of rhabdoid cell lines	8.04E-03	CCND1	1
Cancer	G1 phase	arrest in G1 phase of neuroblastoma cell lines	8.04E-03	CCND1	1
Cancer	G1 phase	arrest in G1 phase of squamous cell carcinoma cell lines	8.04E-03	EGFR	1
Cancer	accumulation	accumulation of colon carcinoma cells	8.04E-03	CCND1	1
Cancer	accumulation	accumulation of skin cancer cell lines	8.04E-03	CCND1	1
Cancer	area	area of tumor	8.04E-03	KDR	1
Cancer	cell spreading	cell spreading of bladder cancer cell lines	8.04E-03	SNAI2	1
Cancer	colony survival	colony survival of breast cancer cell lines	8.04E-03	CA9	1
Cancer	interphase	interphase of rhabdoid cell lines	8.04E-03	CCND1	1
Cancer	mesenchymal tumor	mesenchymal tumor	8.04E-03	SNAI2	1
Cancer	mitogenesis	mitogenesis of colon cancer cell lines	8.04E-03	EGFR	1
Cancer	oral cancer	oral cancer of mice	8.04E-03	CCND1	1
Cancer	outgrowth	outgrowth of ovarian cancer cell lines	8.04E-03	CCND1	1
Cancer	permeability	permeability of endothelioma cell lines	8.04E-03	KDR	1
Cancer	ploidy	ploidy of ovarian cancer cell lines	8.04E-03	EGFR	1
Cancer	re-epithelialization	re-epithelialization of squamous cell carcinoma cell lines	8.04E-03	EGFR	1
Cancer	remission	remission of tumor	8.04E-03	EGFR	1
Cancer	rhabdoid tumor	rhabdoid tumor	8.04E-03	CCND1	1
Cancer	transformation	transformation of carcinoma cells	8.04E-03	FGF4	1

Cancer	transformation	transformation of erythroblasts	8.04E-03	EGFR	1
Cancer	tumor burden	tumor burden of mice	8.04E-03	CCL21	1
Cancer	islet cell tumor	islet cell tumor	8.21E-03	EGFR, KDR	2
Cancer	renal-cell carcinoma	renal-cell carcinoma	9.78E-03	CA9, EGFR, KDR	3
Cancer	development	development of tumor	1.00E-02	CCND1, EGFR, SNAI2	3
Cancer	benign nerve tumor	benign nerve tumor	1.02E-02	GAL, KDR	2
Cancer	developmental process	developmental process of malignant tumor	1.05E-02	CCND1, EGFR, SNAI2	3
Cancer	small-cell carcinoma	small-cell carcinoma	1.07E-02	EGFR, KDR	2
Cancer	interphase	arrest in interphase of breast cancer cell lines	1.12E-02	CCND1, EGFR	2
Cancer	cell stage	arrest in cell stage of breast cancer cell lines	1.12E-02	CCND1, EGFR	2
Cancer	chemotaxis	chemotaxis of carcinoma cell lines	1.20E-02	CCL21	1
Cancer	cell cycle progression	arrest in cell cycle progression of pheochromocytoma cell lines	1.20E-02	GAL	1
Cancer	hyperplasia	hyperplasia of lobules of mammary gland	1.20E-02	FGF4	1
Cancer	hyperplasia	hyperplasia of retina	1.20E-02	CCND1	1
Cancer	tumorigenesis	delay in tumorigenesis of eukaryotic cells	1.20E-02	EGFR	1
Cancer	tumorigenesis	tumorigenesis of intestinal adenoma	1.20E-02	CCND1	1
Cancer	development	development of glioma	1.20E-02	EGFR	1
Cancer	development	development of renal tumor	1.20E-02	CCND1	1
Cancer	adhesion	adhesion of carcinoma cells	1.20E-02	EGFR	1
Cancer	growth	delay in growth of tumor cell lines	1.20E-02	CA9	1
Cancer	developmental process	developmental process of glioma	1.20E-02	EGFR	1
Cancer	cell division process	cell division process of adenocarcinoma cells	1.20E-02	CCND1	1
Cancer	G1 phase	G1 phase of squamous cell carcinoma cell lines	1.20E-02	EGFR	1
Cancer	transformation	transformation of exocrine gland	1.20E-02	CCND1	1

Cancer	transformation	transformation of intestinal cell lines	1.20E-02	EGFR	1
Cancer	transformation	transformation of mammary gland	1.20E-02	CCND1	1
Cancer	G2/M phase transition	arrest in G2/M phase transition of breast cancer cell lines	1.20E-02	CCND1	1
Cancer	colony formation	colony formation of kidney cancer cell lines	1.20E-02	EGFR	1
Cancer	regression	regression of adenoma	1.20E-02	EGFR	1
Cancer	scattering	scattering of neuroblastoma cell lines	1.20E-02	EGFR	1
Cancer	size	size of adenoma	1.20E-02	EGFR	1
Cancer	glioblastoma	glioblastoma	1.23E-02	EGFR, KDR	2
Cancer	invasion	invasion of cell lines	1.35E-02	CCL19, CCL21, EGFR, FGF4, RECK	5
Cancer	developmental process	developmental process of primary tumor	1.35E-02	CCND1, EGFR, SNAI2	3
Cancer	cell spreading	cell spreading of tumor cell lines	1.41E-02	SNAI2, TESK1	2
Cancer	non-small-cell lung carcinoma	non-small-cell lung carcinoma	1.41E-02	EGFR, KDR, SEC61G	3

© 2000-2008 Ingenuity Systems, Inc. All rights reserved.

Supplementary Table S6. Lists of genes identified as overexpression in public datasets.

Genes in recurrent amplicons:	Filter by overexpression in at least one head and neck SCC datasets:	Filter by overexpression in at least one oral datasets:	Overexpressed genes in both head and neck and oral cancer datasets:
ANKRD23	ANKRD39	ANKRD23	ANKRD39
ANKRD39	ARID5A	ASCC3L1	ASCC3L1
ARID3C	ASCC3L1	C9orf100	C9orf100
ARID5A	C9orf100	CA9	CA9
ASCC3L1	CA9	CCL27	CCL27
C9orf100	CCL19	CCND1	CCND1
C9orf127	CCL21	CIAO1	CIAO1
C9orf128	CCL27	CNNM3	CNNM3
C9orf165	CCND1	CNTFR	CPT1A
C9orf23	CD72	CPT1A	CREB3
C9orf24	CEP135	CREB3	DCTN3
C9orf25	CIAO1	DCTN3	EGFR
CA9	CNNM3	EGFR	FGF3
CCDC107	CPT1A	FGF19	FLJ10081
CCL19	CREB3	FGF3	GAL
CCL21	DCTN3	FGF4	LMAN2L
CCL27	EGFR	FLJ10081	LRP5
CCND1	FGF3	GAL	MRPL21
CD72	FLJ10081	GBA2	NCAPH
CEP135	GAL	IL11RA	OPRS1
CIAO1	IGHMBP2	KDR	ORAOV1
CLOCK	LMAN2L	KIAA1754L	SEC61G
CNNM3	LRP5	KIF24	SNAI2
CNNM4	MRPL21	LINCR	TESK1
CNTFR	NCAPH	LMAN2L	TMEM165
CPT1A	NUDT2	LRP5	TPCN2
CREB3	OPRS1	MRGPRD	TPM2
DCTN3	OR2S2	MRGPRF	YWHAZ
DNAI1	ORAOV1	MRPL21	
EFCAB1	RECK	MYEOV	
EGFR	RGP1	NCAPH	
EXOC1	SEC61G	NPR2	
FER1L5	SEMA4C	OPRS1	
FGF19	SNAI2	ORAOV1	
FGF3	TESK1	RUSC2	
FGF4	TLN1	SEC61G	
FLJ10081	TMEM165	SIT1	

GAL	TPCN2	SNAI2
GALT	TPM2	TESK1
GBA2	YWHAZ	TMEM165
HINT2		TPCN2
IGHMBP2		TPM2
IL11RA		UBAP1
KDR		UBAP2
KIAA1161		WDR40A
KIAA1754L		YWHAZ
KIF24		
LGLL338		
LINCR		
LMAN2L		
LOC51252		
LOC730112		
LRP5		
MRGPRD		
MRGPRF		
MRPL21		
MTL5		
MYEOV		
NCAPH		
NMU		
NPR2		
NUDT2		
OPRS1		
OR13J1		
OR2S2		
ORAOV1		
PC-3		
PDCL2		
RECK		
RGP1		
RUSC2		
SAPS3		
SEC61G		
SEMA4C		
SIT1		
SNAI2		
SPAG8		
SRD5A2L		
TESK1		
TLN1		

TMEM165
TPCN2
TPM2
UBAP1
UBAP2
WDR40A
YWHAZ
ZNF706